While these previous findings established that CCR2+/CX3CR1+ MDSCs utilize CCR2 to traffic into the glioma microenvironment, it is unclear what chemokines drive this CCR2-dependent migration. This evidence concerns the gene CCR2 and central nervous system cancer.